Systemic therapy for sarcomatoid renal cell carcinoma

Lance C. Pagliaro, Nizar Tannir, Kanishka Sircar, Eric Jonasch

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

Original languageEnglish (US)
Pages (from-to)913-920
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume11
Issue number6
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Therapeutics
Kidney Neoplasms
Drug Combinations
Biomarkers
Clinical Trials
Pharmaceutical Preparations

Keywords

  • bevacizumab
  • chemotherapy
  • drug therapy
  • immunotherapy
  • kidney neoplasm
  • sarcomatoid neoplasm

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Pagliaro, L. C., Tannir, N., Sircar, K., & Jonasch, E. (2011). Systemic therapy for sarcomatoid renal cell carcinoma. Expert Review of Anticancer Therapy, 11(6), 913-920. https://doi.org/10.1586/era.11.39

Systemic therapy for sarcomatoid renal cell carcinoma. / Pagliaro, Lance C.; Tannir, Nizar; Sircar, Kanishka; Jonasch, Eric.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 6, 06.2011, p. 913-920.

Research output: Contribution to journalReview article

Pagliaro, LC, Tannir, N, Sircar, K & Jonasch, E 2011, 'Systemic therapy for sarcomatoid renal cell carcinoma', Expert Review of Anticancer Therapy, vol. 11, no. 6, pp. 913-920. https://doi.org/10.1586/era.11.39
Pagliaro, Lance C. ; Tannir, Nizar ; Sircar, Kanishka ; Jonasch, Eric. / Systemic therapy for sarcomatoid renal cell carcinoma. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 6. pp. 913-920.
@article{db0f56ef7a5d40d7b2f5ea99bbb7a983,
title = "Systemic therapy for sarcomatoid renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.",
keywords = "bevacizumab, chemotherapy, drug therapy, immunotherapy, kidney neoplasm, sarcomatoid neoplasm",
author = "Pagliaro, {Lance C.} and Nizar Tannir and Kanishka Sircar and Eric Jonasch",
year = "2011",
month = "6",
doi = "10.1586/era.11.39",
language = "English (US)",
volume = "11",
pages = "913--920",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Systemic therapy for sarcomatoid renal cell carcinoma

AU - Pagliaro, Lance C.

AU - Tannir, Nizar

AU - Sircar, Kanishka

AU - Jonasch, Eric

PY - 2011/6

Y1 - 2011/6

N2 - Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

AB - Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. No cellular or genetic biomarker for the sarcomatoid variant has yet been discovered. Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.

KW - bevacizumab

KW - chemotherapy

KW - drug therapy

KW - immunotherapy

KW - kidney neoplasm

KW - sarcomatoid neoplasm

UR - http://www.scopus.com/inward/record.url?scp=79959801387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959801387&partnerID=8YFLogxK

U2 - 10.1586/era.11.39

DO - 10.1586/era.11.39

M3 - Review article

VL - 11

SP - 913

EP - 920

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -